Hematology & Oncology
Showing 1-28 of 28 Results
-
Xi Ying Amanda Chen
Postdoctoral Scholar, Stem Cell Transplantation
BioDr. Chen completed a Bachelor of Science (Honours) at the University of Sydney (NSW, Australia), with majors in Molecular Biology and Immunobiology. She graduated with the University Medal for her Honours research project where she investigated the novel role of DNA damage repair machinery on telomerase recruitment to telomeres. She then undertook her graduate studies at the Peter MacCallum Cancer Centre (The University of Melbourne, VIC, Australia) in the Beavis laboratory, where she developed a CRISPR knock-in strategy to engineer armored CAR T cells to express therapeutic payloads in a tumor-restricted manner. She joined the Porteus laboratory in the Department of Pediatrics at Stanford University in March 2025, where she is developing strategies to enhance gene-edited hematopoietic stem cell transplantation.
-
Aanchal Preet Kaur
Postdoctoral Scholar, Hematology-Oncology
BioDr. Aanchal Preet Kaur is a post-doctoral fellow in the Ramakrishna lab interested in understanding the role of myeloid cells in driving immunosuppression and resistance to CAR T cell therapies in pediatric patients with diffuse midline glioma. Her work involves developing organoid models to study the interaction of myeloid cells and CAR T cells and further employ these models to validate targets identified in patient single cell sequencing data using CRISPR technology.
Dr. Aanchal Preet Kaur received her PhD in Oncology at the University of Nottingham, United Kingdom where she focused on developing dendritic cell vaccines for melanoma. In her earlier post-doctoral work at Providence Cancer Institute with Dr. Michael Gough, she developed spheroid models to study the impact of radiation therapy on immune cell-cancer cell interactions. -
Neetu Saini
Postdoctoral Scholar, Stem Cell Transplantation
BioMy research interests focus on translational human T-cell immunology, with an emphasis on regulatory T cells (Tregs) and their therapeutic potential in restoring immune tolerance and tissue homeostasis. I am particularly interested in engineering FOXP3-programmed CD4⁺ T cells as a stable and functional alternative to conventional Tregs, especially in inflammatory settings where endogenous Tregs may be unstable or dysfunctional. My work integrates gene-editing approaches, immunophenotyping, and human organoid systems to study how these engineered cells interact with epithelial and stem cell compartments, with a focus on mechanisms of tissue repair and immune–epithelial crosstalk in barrier tissues such as the intestine. Moving forward, I aim to advance next-generation cell therapies by combining insights from T-cell biology, tissue biology, and disease modeling to develop durable and clinically relevant strategies for treating immune-mediated and epithelial barrier disorders.
-
Charmaine Fay Carcallas Soco
Postdoctoral Scholar, Stem Cell Transplantation
BioCommunity Engagement Liaison serving the Stanford University Postdoctoral Association (SURPAS)
Co-chair of JEDI-SURPAS
https://surpas.stanford.edu/about/the-surpas-leadership-team/ -
Bing Wang
Postdoctoral Scholar, Stem Cell Transplantation
BioMy academic training and research experience have equipped me with multidisciplinary skills and knowledge of molecular biology and immunology.
I led two projects when I was an undergraduate, in which I got primary academic learning. My team member and I investigated the bacteria content in drinking water from two types of machines that are commonly used in colleges under the guidance of our experimental microbiology teacher Zhihong Zhong. Secondly, we produced a hybridoma cell line secreting monoclonal antibody against the core antigen of the hepatitis C virus (HCV) to develop an ELISA kit for the detection of HCV under the guidance of Dr. Rushi Liu and Minjing Liao.
Thereafter, as a Ph. D. candidate at Xiaoming Feng’s lab, my research primarily focused on understanding the biology of regulatory T cells (Treg) and CD11c+ myeloid cells using cutting-edge single-cell sequencing and conditional knockout mice under healthy and disease conditions. We first revealed the heterogeneity and bifurcated differentiation pathway of human Tregs from normal donors and transplanted patients at the single-cell transcriptome level. A subsequent first and corresponding author publication identified a key innate responsive protein in CD11c+ alveolar macrophages, NRP2, that protects mice from lung injury via promoting the phagocytosis of neutrophils. I also participated in two projects regarding the role of a serine/threonine kinase, LKB1, in mice CD11c+ dendritic cells from lymphoid tissues and adipose tissue with diet-induced obesity. These academic experiences guided me into a strong passion and independent capacities for biomedical studies.
For my postdoctoral training, I will focus on developing Treg therapies and genetic stem cell therapy to cure patients with IPEX syndrome (a severe autoimmune disease) at preclinical and clinical stages, and other immune disorders. My sponsor Dr. Rosa Bacchetta is a well-known leader in treating IPEX patients and developing Treg therapies. My co-mentor Dr. Maria Grazia Roncarolo is a well-recognized pediatric immunologist and also one of the pioneers in the stem cell and gene therapy field, who discovered the type 1 regulatory T cells or Tr1 cells and translate the scientific discoveries into novel Treg therapies. Both of them have an excellent record of training postdoctoral fellows. The proposed projects will provide me with great opportunities in cutting-edge technology and translational research and outline a set of career development including grant writing, public presentation, and lab management, which will enhance my ability to become an independent investigator and help me to reach my goal of developing efficient and safe Treg therapies for a wide range of immune disorders and associated human diseases. -
Wenjun Wang
Postdoctoral Scholar, Stem Cell Transplantation
Current Research and Scholarly InterestsMy postdoctoral research focuses on investigating novel therapy for childhood leukemias.
-
Zeyuan Zhang
Postdoctoral Scholar, Hematology-Oncology
BioZeyuan Zhang, Ph.D., is a Postdoctoral Scholar at Stanford University in the laboratory of Glaivy Batusli, where he is conducting research on the evolution of antibody development against the coagulation protein factor IX in hemophilia B disease models. He earned his Ph.D. in Biomedical Science from the University of Iowa, focusing on cell and developmental biology.
Dr. Zhang’s research centers on the molecular mechanisms underlying metabolic disease, with particular emphasis on organelle dysfunction in obesity. His work has provided insights into GSNOR enzymatic activity, lysosomal dysfunction, and inflammatory stress in metabolic regulation. He has also investigated transcriptional mechanisms contributing to obesity-associated hepatic dysfunction and adipose tissue homeostasis. Prior to joining Stanford, he worked as a Scientist I at Altos Labs, where he studied hepatocyte-specific rejuvenation reprogramming in fatty liver disease.
His technical expertise includes multi-omics approaches, RNA sequencing, chromatin immunoprecipitation, high-resolution respirometry, advanced imaging techniques, and in vivo mouse models. He also has extensive experience in primary cell isolation and histological analysis.
Dr. Zhang is interested in translational research that connects molecular mechanisms to therapeutic strategies, with the goal of developing innovative treatments for metabolic diseases.
